Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on
Upcoming FDA Advisory Committee Meeting
ATLANTA, Oct. 31, 2013
ATLANTA, Oct. 31, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that after the market close on Monday, November 11, 2013, it
will release its third quarter fiscal year 2013 financial results. An
investor conference call will follow on the same day at 4:30 p.m. ET to
discuss those results and provide an update regarding its upcoming meeting
with the U.S. Food and Drug Administration's Dermatologic and Ophthalmic Drugs
Advisory Committee in January 2014 to discuss the Company's New Drug
Application for ILUVIEN.
The conference call will be hosted by Dan Myers, President and Chief Executive
Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or
(253) 237-1165 (international). A live webcast will be available on the
Investor Relations section of the corporate website at
A replay of the conference call will be available beginning November 11, 2013
at 7:30 p.m. ET and ending on November 17, 2013 by dialing (855) 859-2056
(U.S. and Canada) or (404) 537-3406 (international), Conference ID Number:
92324341. A replay of the webcast will be available on the corporate website
for one week, through November 17, 2013.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina.
ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained
release intravitreal implant used to treat vision impairment associated with
chronic DME considered insufficiently responsive to available therapies. Each
ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering
sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is
injected in the back of the patient's eye to a position that takes advantage
of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle,
which allows for a self-sealing wound. In the FAME™ Study, the most frequently
reported adverse drug reactions included cataract development and increased
ocular pressure. ILUVIEN has not been approved for sale in the U.S. ILUVIEN is
approved in the United Kingdom, Germany, France Austria, Portugal and Spain
and pending approval in Italy. In addition, Alimera has filed with the
Medicines and Healthcare Products Regulatory Agency in the United Kingdom
(U.K.) as the Reference Member State for 10 additional European Union country
approvals through the Mutual Recognition Procedure.
SOURCE Alimera Sciences, Inc.
Press spacebar to pause and continue. Press esc to stop.